Approved · Notification · Phase 1 · decided in 26 days, 4 May 2026
Eli Lilly and Company, a US-based pharmaceutical company, acquired 100% of the shares in Orna Therapeutics Holdings, LLC, a US-based pre-clinical biotechnology company. This share acquisition enhances Eli Lilly's human pharmaceutical product portfolio with Orna Therapeutics' engineered circular RNA therapeutics and lipid nanoparticle delivery technologies for autoimmune disorders and cancer.
Eli Lilly and Company ( Eli Lilly ) proposes to acquire 100% of the issued shares in Orna Therapeutics Holdings, LLC ( Orna Therapeutics ) (the Acquisition ). Eli Lilly is a US-based pharmaceutical company, which discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. Eli Lilly is headquartered in Indianapolis, US and is publicly listed on the New York Stock Exchange. Eli Lilly has an Australian subsidiary that registers and markets medicine in Australia. Orna Therapeutics is a US-based pre-clinical biotechnology company developing a new class of engineered circular RNA ( oRNA ) therapeutics and immune tropic lipid nanoparticles ( LNP ) delivery technologies for the treatment of autoimmune disorders, and cancer conditions. Orna Therapeutics has a pipeline consisting of two pre-clinical in vivo Chimeric Antigen Receptor T-cell ( CAR-T ) therapies, designed to treat B cell-driven autoimmune diseases.